The researchers first tested their hypothesis by delivering ODN directly to the hindbrain of rats. Once treated, the rats ...

The first human-tested weight-loss drug that burns calories through creatine-based heat generation, without reducing appetite, has successfully completed its Phase I trial.

This COX-2 upstart performed exceedingly well in its first head-to-head comparison against opioids. Could Imrecoxib join ...